The 2026 European Society for Medical Oncology guidelines reshape metastatic breast cancer treatment by shifting antibody-drug conjugates into the first-line setting, utilizing oral endocrine therapies, and anchoring management in molecular profiling. A perspective article published in Clinical Breast Cancer on October 7, 2026, details how these updated recommendations compare with the previous version 1.2 through the insights of European breast oncology experts Giuseppe Curigliano, Luís Castelo-Branco, Volkmar Müller, and Nadia Harbeck.
While metastatic breast cancer remains treatable rather than curable, with U.S. National Cancer Institute SEER program data reporting a five-year relative survival rate of approximately 34% (specifically 33.8%) for women diagnosed with distant-stage disease between 2016 and 2022, research progress continues to alter treatments.
Expanding Antibody-Drug Conjugates into First-Line Treatment
The most consequential changes in the 2026 framework involve expanding antibody-drug conjugates into first-line treatment, specifically trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer and TROP2-directed antibody-drug conjugates for triple-negative breast cancer. For hormone receptor-positive and HER2-negative disease, the guidelines refine molecularly guided selection through alterations such as ESR1, PIK3CA, AKT1, and PTEN.
The recommendations explicitly separate endocrine-sensitive and endocrine-resistant disease. For endocrine-sensitive cases, aromatase inhibitors combined with CDK4/6 inhibitors remain foundational, supported by trial evidence from MONALEESA-2, MONARCH-3, and PALOMA-2, with ribociclib demonstrating a statistically significant overall survival benefit in the first-line setting. Conversely, endocrine resistance shifts the approach, increasing reliance on molecular profiling. The INAVO120 trial established the value of combining inavolisib, palbociclib, and fulvestrant in PIK3CA-mutated, endocrine-resistant advanced breast cancer, significantly improving progression-free survival (HR 0.43; p<0.001) and overall survival (HR 0.67; p=0.02).
Translating Advances into Clinical Practice Introduces Persistent Challenges
Despite the expansion of oral endocrine therapies, molecularly targeted combinations, and maintenance options, the experts emphasize that a growing number of therapeutic choices does not automatically translate into better outcomes. Translating these advances into clinical practice introduces persistent challenges regarding biomarker testing, treatment sequencing, toxicity management, and equitable access to innovative therapies.
Researchers Lead Shift Toward Personalized Breast Cancer Treatment
Researchers are leading a shift toward personalized breast cancer treatment, expanding options with hormone-based therapies, targeted treatments, and drug-delivery approaches that directly attack cancer cells. Much of this work has been initiated or led by Dana-Farber breast cancer doctors, as noted by Erica Mayer, director of breast cancer clinical research at Dana-Farber. For patients such as Siobhan Donovan, a mother diagnosed with stage IV/metastatic breast cancer during pregnancy who feared not living to see her children know her, these medical advancements have extended time with her kids and transformed her outlook from fear to planning for the future. Now I’m looking ahead, and — ‘What’s next?’ and ‘What can’t we do? Why not? Let’s do it!
Donovan said.
